Kinase Inhibitor News and Research

RSS
A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

CML treatment-free remission criteria outlined

CML treatment-free remission criteria outlined

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

Bosutinib shows 'low' vascular, cardiac event risk profile

Bosutinib shows 'low' vascular, cardiac event risk profile

Frontline nilotinib supported for newly diagnosed CP-CML

Frontline nilotinib supported for newly diagnosed CP-CML

Pre-TKI cytokine profiling predicts CP-CML outcome

Pre-TKI cytokine profiling predicts CP-CML outcome

Additional chromosomal abnormalities prognostic for CML

Additional chromosomal abnormalities prognostic for CML

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Vascular events in CML may not be linked to TKI therapy

Vascular events in CML may not be linked to TKI therapy

Real-life data show feasibility of imatinib discontinuation in CML

Real-life data show feasibility of imatinib discontinuation in CML

New study reveals why certain cancer drugs not always effective in halting tumor growth

New study reveals why certain cancer drugs not always effective in halting tumor growth

FDA-approved VENTANA anti-ALK CDx more accurate than commonly used IHC assay for patient selection

FDA-approved VENTANA anti-ALK CDx more accurate than commonly used IHC assay for patient selection

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Mtss1 'tumour suppressor' for CML

Mtss1 'tumour suppressor' for CML

CTI BioPharma announces Q4 and FY 2015 earnings

CTI BioPharma announces Q4 and FY 2015 earnings

Fasudil improves memory in rats, promotes degradation of toxic tau in the eyes of fruit flies

Fasudil improves memory in rats, promotes degradation of toxic tau in the eyes of fruit flies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.